Evidence record 9749 · automatically gathered

Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective

Artificial Intelligence (AI) has the disruptive potential to transform patients' lives via innovations in pharmaceutical sciences, drug development, clinical trials, and manufacturing. However, it presents significant challenges, ethical concerns, and risks across sectors and societies. AI's rapid advancement has revealed regulatory gaps as existing public policies struggle to keep pace with the challenges posed by these emerging technologies. The term AI itself has become commonplace to argue t

Record details

Published: 3 January 2025
Source: OpenAlex
Category: Research
Topics: Regulation · Healthcare · Biotech
Retrieved: 14 July 2026

source-onlyevidence status

These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.

How to cite this record

ethics.ai (3 January 2025), “Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective,” evidence record 9749, https://ethics.ai/record/9749 (originally published by OpenAlex).

JSON

Use and limitations

This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.